Jensen J, Riis B J, Christiansen C
Br J Obstet Gynaecol. 1987 Feb;94(2):136-41. doi: 10.1111/j.1471-0528.1987.tb02340.x.
Serum lipids and lipoproteins were studied in 76 healthy postmenopausal women treated for 1 year with either oestradiol valerate sequentially combined with the anti-androgenic progestogen cyproterone acetate (CPA) or placebo. The women were examined every 3 months between days 18 and 21 of the tablet cycle, where the progestogen had been added to the oestrogen for at least 6 days. Combined oestrogen-CPA therapy resulted in significantly reduced levels of total serum cholesterol and LDL-cholesterol at all examinations, but serum triglycerides and HDL-cholesterol levels were similar in the two groups. Total serum cholesterol and LDL-cholesterol were reduced by approximately 5% (P less than 0.01) and 8% (P less than 0.01), respectively, after 1 year of combined oestrogen-CPA therapy in comparison with both the initial values and the placebo group but serum triglycerides and HDL-cholesterol levels were unchanged in both groups.
对76名健康绝经后女性进行了血清脂质和脂蛋白研究，这些女性接受了为期1年的治疗，治疗方案为戊酸雌二醇序贯联合抗雄激素孕激素醋酸环丙孕酮（CPA）或安慰剂。在片剂周期的第18至21天之间，每3个月对这些女性进行一次检查，此时孕激素已添加到雌激素中至少6天。联合雌激素-CPA治疗在所有检查中均导致血清总胆固醇和低密度脂蛋白胆固醇水平显著降低，但两组的血清甘油三酯和高密度脂蛋白胆固醇水平相似。与初始值和安慰剂组相比，联合雌激素-CPA治疗1年后，血清总胆固醇和低密度脂蛋白胆固醇分别降低了约5%（P<0.01）和8%（P<0.01），但两组的血清甘油三酯和高密度脂蛋白胆固醇水平均未改变。
